Format

Send to

Choose Destination
J Cell Biochem. 2018 Jun;119(6):4967-4974. doi: 10.1002/jcb.26742. Epub 2018 Mar 9.

Jolkinolide B inhibits glycolysis by downregulating hexokinase 2 expression through inactivating the Akt/mTOR pathway in non-small cell lung cancer cells.

Author information

1
Department of Cardiothoracic Surgery, Huaihe Hospital of Henan University, Kaifeng, P.R. China.
2
Minsheng College, Henan University, Kaifeng, P.R. China.

Abstract

Jolkinolide B (JB), a bioactive compound isolated from herbal medicine, has been found to inhibit tumor growth by altering glycolysis. However, whether glycolysis is influenced by JB in non-small cell lung cancer (NSCLC) cells and the mechanism remain unknown. The aim of the present study was to evaluate the effect of JB on the glycolysis in NSCLC cells and the underlying molecular mechanism. The results showed that JB treatment inhibited cell viability of A549 and H1299 cells in a concentration-dependent manner. JB reduced the glucose consumption, lactate production, and HK2 expression. The expressions of p-Akt and p-mTOR were also decreased by JB treatment. Knockdown of HK2 reduced glucose consumption and lactate production. Inhibition of the Akt/mTOR pathway decreased HK2 expression and inhibited glycolysis. In conclusion, the results indicated that JB inhibits glycolysis by down-regulating HK2 expression through inactivating the Akt/mTOR pathway in NSCLC cells, suggesting that JB might be a potential therapeutic agent for the treatment of NSCLC.

KEYWORDS:

Akt/mTOR pathway; glycolysis; hexokinase 2; jolkinolide B; non-small cell lung cancer

PMID:
29384225
DOI:
10.1002/jcb.26742
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center